Peer-reviewed veterinary case report
How a macrophage protein affects chronic kidney disease in cats
By Tezuka, Tetsushi et al.·Published in Veterinary journal (London, England : 1997)·2026·The Institute for AIM Medicine (IAM), Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A clinical impact of apoptosis inhibitor of macrophage on feline chronic kidney disease.
- Species:
- cat
Plain-English summary
A group of cats with advanced chronic kidney disease (CKD) were treated with a new therapy called recombinant AIM (rAIM) to see if it could help improve their condition. The study involved 216 cats, and those who received rAIM had a significantly longer survival time compared to those who did not receive treatment. Specifically, cats treated with mouse rAIM or feline rAIM had an 83% and 80% survival rate at 360 days, respectively, while only 20% of the untreated cats survived that long. Additionally, rAIM helped prevent the worsening of kidney function and reduced harmful toxins in the blood. This suggests that rAIM could be a promising treatment option for cats suffering from advanced CKD.
People also search for: cat chronic kidney disease treatment · feline kidney disease survival rate · rAIM for cats kidney disease
Abstract
Cats are highly susceptible to chronic kidney disease (CKD), for which effective treatments remain unavailable. We previously reported a genetic deficiency in activating apoptosis inhibitor of macrophages (AIM) in cats. Based on a hypothesis that the deficiency in AIM activation may contribute to the high susceptibility of cats to CKD, we investigated clinical impacts of recombinant AIM (rAIM) treatment in cats with advanced CKD, as an exploratory, non-pivotal study. 216 CKD cats were screened and those harboring serum creatinine concentrations between 2.9 and 5.0 mg/dL, including 26 with ≥ 5 µg/mL serum indoxyl sulfate (IS) concentrations and 9 with < 5 μg/mL IS, were enrolled into the study. Of the 26 cats, 6 received mouse rAIM administrations, 5 received feline rAIM, and 15 served as non-treated controls. Their survival was monitored for 360 days, and kidney biomarkers, metabolomic profiles, as well as sphingolipids in serum were assessed. The median survival time of non-treated controls was 167 days (95 % confidence interval [CI]: 116-217), whereas rAIM treatment significantly extended survival, with a cumulative survival rate of 0.83 (95 % CI: 0.53-1.0) at 360 days by mouse rAIM and 0.8 (95 % CI: 0.44-1.0) by feline rAIM compared to 0.20 (95 % CI: 0.0-0.40) in controls. Additionally, rAIM prevented the worsening of kidney biomarkers and uremic toxins, restoring serum sphingomyelins that reduce inflammation and fibrosis. The 9 cats with lower IS concentrations showed 100 % survival at 360 days without rAIM treatment. These findings support the use of AIM-based therapies against advanced CKD in cats.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41485732/